Literature DB >> 35869413

Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.

Dhanushi Rupasinghe1, Jun Yong Choi2, Evy Yunihastuti3, Sasisopin Kiertiburanakul4, Jeremy Ross5, Penh Sun Ly6, Romanee Chaiwarith7, Cuong Duy Do8, Yu-Jiun Chan9, Nagalingeswaran Kumarasamy10, Anchalee Avihingsanon11, Adeeba Kamarulzaman12, Suwimon Khusuwan13, Fujie Zhang14, Man Po Lee15, Kinh Van Nguyen16, Tuti Parwati Merati17, Sashikala Sangle18, Ng Oon Tek19,20,21, Junko Tanuma22, Rossana Ditangco23, Benedict Lim Heng Sim24, Sanjay Pujari25, Awachana Jiamsakul1.   

Abstract

Liver disease is a growing burden among people living with HIV (PLHIV) in resource-limited settings. As an indicator of liver disease, risk factors of high alanine aminotransferase (ALT) and cirrhosis were assessed among PLHIV in the TREAT Asia HIV Observational Database (TAHOD). Patients on combination antiretroviral therapy (cART) with a pre-cART ALT measurement and at least one follow-up ALT measurement were included. Factors associated with high ALT (ALT levels > 5 times its upper limit of normal) were analyzed using repeated measure logistic regression over a 10-year follow-up period. Liver cirrhosis was defined as having an AST to Platelet Ratio Index score > 1.5, fibrosis-4 score > 3.25, or a clinical diagnosis of cirrhosis. Cox regression analysis stratified by site was used to analyze factors associated with cirrhosis among those in follow-up after 2015. Of 5182 patients, 101 patients (1.9%) had high ALT levels with hepatitis C virus (HCV) antibody positive (odds ratio [OR]: 4.98, 95% confidence interval [CI]: 2.82-8.77, p < 0.001) and ever high alcohol consumption (OR: 2.33, 95% CI: 1.00-5.46, p = 0.050) as likely factors. Among 6318 PLHIV in the liver cirrhosis analysis, 151 (2%) developed cirrhosis (incidence rate = 0.82 per 100 person-years). Those HCV-antibody positive (hazard ratio [HR]: 5.54, 95% CI: 3.75-8.18, p < 0.001) and had high alcohol consumption (HR: 2.06, 95% CI: 1.23-3.45, p = 0.006) were associated with liver cirrhosis. HCV-antibody positive and high alcohol consumption are factors associated with high ALT. With raised ALT levels as a known factor associated with liver cirrhosis, greater efforts are required in managing ALT levels and reducing the risk of developing liver cirrhosis among those positive for HCV-antibody and those who consume alcohol.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  ALT elevations; Asia-Pacific; HIV; cirrhosis

Mesh:

Substances:

Year:  2022        PMID: 35869413      PMCID: PMC9534455          DOI: 10.1002/jmv.28019

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


  28 in total

1.  Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.

Authors:  W Ray Kim; Steven L Flamm; Adrian M Di Bisceglie; Henry C Bodenheimer
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

2.  Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study.

Authors:  Yi-Wen Huang; Ting-Chuan Wang; Shih-Chang Lin; Han-Yu Chang; Ding-Shinn Chen; Jui-Ting Hu; Sien-Sing Yang; Jia-Horng Kao
Journal:  Clin Infect Dis       Date:  2013-09-18       Impact factor: 9.079

3.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

Review 4.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

Review 5.  Impact of diabetes on the severity of liver disease.

Authors:  Ingrid J Hickman; Graeme A Macdonald
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

6.  Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

Authors:  A Katrina Loomis; Shaum Kabadi; David Preiss; Craig Hyde; Vinicius Bonato; Matthew St Louis; Jigar Desai; Jason M R Gill; Paul Welsh; Dawn Waterworth; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

7.  The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections.

Authors:  Richard K Sterling; Steven Chiu; Kenny Snider; Daniel Nixon
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

8.  The TREAT Asia HIV Observational Database: baseline and retrospective data.

Authors:  Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas I Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.771

Review 9.  Trends in the management and burden of alcoholic liver disease.

Authors:  Philippe Mathurin; Ramon Bataller
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.